Literature DB >> 3141722

Nasopharyngeal carcinoma in India: end-result analysis (1980-1984).

S B Koppikar1, S H Advani, R Gopal, K A Dinshaw, S C Pande, C N Nair, S Tapan, K S Nadkarni, A Borges, P B Desai.   

Abstract

One hundred fifty patients with nasopharyngeal carcinoma were treated at the Tata Memorial Hospital from January 1980 to December 1984. Lymphoepithelioma was the most common histologic subtype. Advanced disease in stages III and IV was seen in 22.66% and 72% of the patients, respectively. Complete remission was obtained in 80 of 120 patients (66.66%) with radiation alone and in 19 of 30 patients (63.3%) who received preradiation chemotherapy and radiation. Age, sex, and histology did not influence the rate of complete remission. The N0-1 nodal status group had a significantly better response of 81% and 36% survival, as compared with the N2-3 group with a 55% response and 20% survival. Only 30 of those who received radiation alone and 10 of those who received preradiation chemotherapy are disease-free for a median period of 24 months. Twenty-six relapses have occurred within a median period of 12 months. The 5-year actuarial disease-free survival is 13%. This indicates the need for an early diagnosis and combined aggressive treatment to improve survival.

Entities:  

Mesh:

Year:  1988        PMID: 3141722     DOI: 10.1002/jso.2930390309

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  2 in total

1.  A benchmark study on 883 nasopharyngeal cancer patients treated in two Italian centres from 1977 to 2000. Part I: Evolving technical choices and survival.

Authors:  S Tonoli; S M Magrini; L Costa; F Paiar; G Simontacchi; V Scotti; N Pasinetti; R Barca; D Barbieri; A De Stefani; E Cellai; M Buglione; G Biti
Journal:  Radiol Med       Date:  2011-11-17       Impact factor: 3.469

2.  Can global variation of nasopharynx cancer be retrieved from the combined analyses of IARC Cancer Information (CIN) databases?

Authors:  Xin Sun; Li-Ping Tong; Yu-Tong Wang; Yong-Xiang Wu; Hong-Shen Sheng; Lian-Jun Lu; Wen Wang
Journal:  PLoS One       Date:  2011-07-07       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.